56. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI:10.4161/ORG.7.1.14027.
57. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI:10.1056/NEJM199108083250604.
58. Henon P. Thrombotic thrombocytopenic purpura: Clinical results of a French controlled trial. Transfus Sci. 1992;13(1):63–72. DOI:10.1016/0955-3886(92)90123-X.
59. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320–8. DOI:10.1046/J.1526-0968.2002.00390.X.
60. Rock G., Shumak K.H., Sutton D.M., et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94(2):383–6. DOI:10.1046/J.1365-2141.1996.D01-1800.X.
61. Mazepa M.A., Raval J.S., Brecher M.E., et al. Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. J Clin Apher. 2018;33(3):291–6. DOI:10.1002/JCA.21600.
62. Altuntas F., Aydogdu I., Kabukcu S., et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2007;36(1):57–67. DOI:10.1016/J.TRANSCI.2006.05.014.
63. Zeigler Z.R., Shadduck R.K., Gryn J.F., et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher. 2001;16(1):19–22. DOI:10.1002/JCA.1003.
64. Lin Q., Fan L., Huang H., et al. Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Biomed Res Int. 2019;2019. DOI:10.1155/2019/1756109.
65. Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985;65(5):1232–6.
66. Stefanello B., De Paula E.V., Andrade Orsi F., et al. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. J Clin Apher. 2014;29(6):311–5. DOI:10.1002/JCA.21336.
67. Raife T.J., Friedman K.D., Dwyre D.M. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion. 2006;46(1):74–9. DOI:10.1111/J.1537-2995.2005.00674.X.
68. Rock G., Ahluwalia N., Anderson D. Metalloprotease levels are variably altered in thrombotic thrombocytopenic patients at presentation and after plasma exchange with either cryosupernatant plasma or fresh frozen plasma. Blood. 2001;102:539a.
69. Thejeel B., Garg A.X., Clark W.F., et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol. 2016;91(6):623–30. DOI:10.1002/AJH.24339.
70. Sayani F.A., Abrams C.S. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860–7. DOI:10.1182/BLOOD-2014-11-551580.
71. Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI:10.1056/NEJM199108083250605.
72. Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high‐dose corticosteroid. Vol. 41, Am J Hematol. Am J Hematol; 1992. p. 69. DOI:10.1002/ajh.2830410119.
73. Balduini C.L., Gugliotta L., Luppi M., et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591–6. DOI:10.1007/S00277-009-0877-5.
74. Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI:10.1111/J.1538-7836.2006.01879.X.
75. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI:10.1002/jca.20091.
76. Regazzi M.B., Iacona I., Avanzini M.A., et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785–92. DOI:10.1097/01.FTD.0000184162.60197.C1.
77. Tobinai K., Igarashi T., Itoh K., et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(5):821–30. DOI:10.1093/ANNONC/MDH176.
78. Chen H., Fu A., Wang J., et al. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI:10.1177/0300060517695646.
79. McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI:10.1111/J.1538-7836.2010.03818.X.
80. Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI:10.1182/BLOODADVANCES.2017008268.